Anthony Mangum
Peer-Reviewed Article Reporting DiscGenics’ ...

The International Society for the Advancement of Spine Surgery has recognized the peer-reviewed article reporting DiscGenics’ Phase I/II clinical trial results as one of the best and most influential articles published in the International Journal of Spine Surgery in 2024.

Peer-Reviewed Article Reporting DiscGenics’ Cell Therapy Phase I/II Study Results Receives International Journal of Spine Surgery Best Paper Award
Anthony Mangum
DiscGenics Announces US FDA Approval to Proceed ...

DiscGenics has gained acceptance from the U.S. FDA for the clinical protocols and Chemistry, Manufacturing, and Controls (CMC) clinical development plan for Phase III clinical program of its allogeneic, injectable disc progenitor cell therapy (IDCT or rebonuputemcel) for painful lumbar degenerative disc disease (DDD), allowing the study to proceed.

DiscGenics Announces US FDA Approval to Proceed with Phase III Clinical Evaluation of Allogeneic, Injectable Disc Progenitor Cell Therapy for Symptomatic Lumbar Degenerative Disc Disease
Anthony Mangum
The International Journal of Spine Surgery Has ...

The International Journal of Spine Surgery publishes results from the combined Phase I/Phase II, first-in-human clinical study of an allogeneic disc progenitor cell therapy (IDCT or rebonuputemcel) for painful lumbar degenerative disc disease.

The International Journal of Spine Surgery Has Published Results from an FDA-Approved Study of an Allogeneic Disc Progenitor Cell Therapy for the Treatment of Adults with Lumbar Disc Degeneration
Anthony Mangum
DiscGenics to Present at Canaccord Genuity 2024 ...

DiscGenics CEO and Chairman, Flagg Flanagan will present at Canaccord Genuity 2024 Musculoskeletal Conference taking place in San Francisco on Monday, February 12, 2024.

DiscGenics to Present at Canaccord Genuity 2024 Musculoskeletal Conference
Anthony Mangum
DiscGenics Announces Research Collaboration ...

DiscGenics has announced a basic science Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Veterans Affairs (VA) to assess the feasibility of using DiscGenics’ proprietary Discogenic Cells with the VA’s whole, tissue-engineered endplate-modified disc-like angle ply structure (eDAPS).

DiscGenics Announces Research Collaboration with the U.S. Department of Veterans Affairs for Tissue-Engineered Discs with Discogenic Cells

patients

DiscGenics Launches DDDtrial.com for Patients with Chronic Low Back Pain Associated with Degenerative Disc Disease

SALT LAKE CITY, Utah — April 9, 2026 — DiscGenics, Inc. today announced the launch of DDDtrial.com, a patient-focused website created to help individuals learn more about a Phase 3 clinical research study of IDCT for chronic low back pain associated with degenerative disc disease (DDD) of the lumbar spine. The website offers study information and a convenient pre-screening process for individuals who may be eligible to participate.

IDCT is an investigational injectable disc cell therapy using DiscGenics’ proprietary Discogenic Cells. The Phase 3 study evaluates IDCT as a potential non-surgical treatment for degenerative disc disease of the lower spine.

Individuals may qualify for the study if they are 18 to 75 years old1, have experienced chronic low back pain for at least six months, have lumbar DDD that is diagnosed or suspected, and are able to return for follow-up visits over approximately two years. For qualified participants, no study-related costs are required, compensation may be available, and participants may be assigned a study injection.

“Chronic low back pain can have a significant impact on daily life, and many patients continue to seek non-surgical treatment options,” said Flagg Flanagan, Chairman and CEO of DiscGenics, “With DDDtrial.com, we aim to make it easier for people to learn about this Phase 3 study and determine whether they may be eligible to participate.”

About the Phase 3 Study

The Phase 3 clinical research study is evaluating IDCT as a non-surgical treatment under investigation for degenerative disc disease of the lower spine. The website is intended to support awareness and pre-screening for potential participants.

You May Qualify If You:

  • Are 18–75 years old

  • Have had chronic low back pain for 6 months or longer

  • Have lumbar degenerative disc disease, diagnosed or suspected

  • Are able to return for follow-up visits for about 2 years

To learn more or complete the pre-screen, visit DDDtrial.com.

About IDCT (rebonuputemcel)
IDCT is an Investigational New Drug (IND enabled) allogeneic cell therapy that utilizes Discogenic Cells derived from donated adult intervertebral disc tissue. It is designed to be administered via injection as a non-surgical treatment intended to reduce pain and improve function in patients with lumbar disc degeneration.

About DiscGenics
DiscGenics is a privately held, late-stage clinical, biopharmaceutical company developing cell-based regenerative therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. DiscGenics’s first product candidate, IDCT (rebonuputemcel), is an allogeneic, injectable discogenic progenitor cell therapy for symptomatic, lumbar disc degeneration. IDCT is a mixture of live Discogenic Cells, which are a manufactured progenitor cell population derived from donated adult human intervertebral disc tissue, and a viscous carrier. IDCT has been granted regenerative medicine advanced therapy (RMAT) and Fast Track designations by the U.S. Food and Drug Administration. As the only company in the world to develop an allogeneic cell therapy derived from intervertebral disc cells to treat diseases of the disc, DiscGenics has a unique opportunity to offer a non-surgical, potentially regenerative solution for the treatment of patients suffering from the debilitating effects of back pain.

DiscGenics has developed a proprietary, commercial-scale, in-house allogeneic cell manufacturing process and built and qualified a cGMP facility at its Salt Lake City, Utah headquarters.

For more information, visit discgenics.com

Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the therapeutic potential, regulatory status, commercialization timing, market opportunity, post-marketing commitments, and future development of IDCT. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including regulatory developments, clinical outcomes, manufacturing readiness, reimbursement decisions, commercialization execution, and other factors. DiscGenics undertakes no obligation to update these statements except as required by law.